Elderly patients with malignant lymphoma with rituximab plus CHOP chemotherapy for nursing.docVIP

 PAGE \* MERGEFORMAT 11 Elderly patients with malignant lymphoma with rituximab plus CHOP chemotherapy for nursing Of: the Xiaojuan, Baiyun Juan, Wang Xiaoyuan [Abstract] summary review our department 50 cases of elderly lymphoma patients with rituximab plus CHOP chemotherapy treatment care and therapeutic observation. This group of 50 cases of elderly lymphoma patients received rituximab in combination with CHOP chemotherapy treatment, after careful care, reduce side effects of chemotherapy in this group of patients, the treatment effect is obvious, 47 patients successfully completed 10 courses of treatment, 3 patients died due to sudden cardiac diseases. by our clinical care, fully proved that this scheme is safe and effective for the future Nursing care of elderly patients before and after chemotherapy provided a valuable experience. [Keywords:] old; malignant lymphoma; rituximab; Care With the increase in the proportion of elderly population, senior citizens, are highly valued patient care. In recent years, senior citizens gradually become malignant lymphoma of the common diseases in elderly patients, patients continue to increase. As the elderly patients with multiple diseases, treatment is difficult to death rate, in the treatment of the nursing process, the treatment of such patients is not entirely according to the conventional regimen. rituximab plus CHOP chemotherapy for the treatment of patients with malignant lymphoma have a certain effect, rituximab plus CHOP embedded program is a mouse type of anti-CD20 antibodies together, it can promote apoptosis of lymphoma tissue, inhibit tumor cell proliferation, drug resistance of tumor cells has been re sensitive to chemotherapy. R-CHOP scheme (R-Rituximab 600 mg / d, C- cyclophosphamide 0.8 g / d, H-doxorubicin 20 mg / d, O-vindesine 2 mg / d, P-dexamethasone 5 mg / d) gradually becomes an effective chemotherapy, but This chemotherapy regimen for elderly patients with malignant lymphoma is not